Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ASGR1 | P07306 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.32 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371582 | 0.91 | MAPK1 (0.33) | MAPK1L3MBTL1CNR1CNR2 | |
| SCHEMBL12371580 | 0.91 | MAPK1 (0.33) | MAPK1L3MBTL1CNR1CNR2 | |
| SCHEMBL12600388 | 0.91 | MAPK1 (0.33) | MAPK1L3MBTL1CNR1CNR2 | |
| SCHEMBL4204268 | 0.90 | TLR4 (0.37) | MAPK1CNR1CNR2 | |
| SCHEMBL4201778 | 0.85 | GBA1 (0.31) | — | |
| SCHEMBL12560736 | 0.85 | MAPK1 (0.40) | MAPK1L3MBTL1ASGR1LGALS8LGALS3 | |
| SCHEMBL7566809 | 0.85 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL4198168 | 0.85 | GBA1 (0.36) | MAPK1 | |
| SCHEMBL4192378 | 0.83 | GBA1 (0.33) | — | |
| SCHEMBL7141048 | 0.82 | TLR4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399634-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | LTB4R2, LTB4R, LITAF | MAPK1 2123/4885L3MBTL1 94/4885ASGR1 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.